Reverse-payment agreements remain low

Washington, D.C. (December 15, 2020) -- The Federal Trade Commission said the number of final patent settlements entered by drugmakers in fiscal year 2017 was close to the record high of fiscal year 2016. But those that include the types of reverse payments that are likely to be anticompetitive remain very low, said the staff report....

Related Sections